Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal International Journal of Multidisciplinary Sciences and Arts BULLET : Jurnal Multidisiplin Ilmu
Anirudh Mehta
Unknown Affiliation
Humanities Computer Science & IT Economics, Econometrics & Finance Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Nursing

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
COVID-19 as a Catalyst for Innovation: Pharmaceutical Industry Manufacturing Techniques and Management of Endemic Diseases Anirudh Mehta; Varun Choudhary
International Journal of Multidisciplinary Sciences and Arts Vol. 2 No. 4 (2023): International Journal of Multidisciplinary Sciences and Arts, Article October 2
Publisher : Information Technology and Science (ITScience)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47709/ijmdsa.v2i2.2996

Abstract

The lockdown measures of the Covid-19 pandemic have significantly impacted change in pharmaceutical manufacturing technology, regulation and global supply chains. To respond to unprecedented global demand, significant advances took place and these include platform-based manufacturing such as mRNA and viral vector vaccines, shift to continuous manufacture. Indeed, reducing harm to the buying public through the preservation of product safety and quality, the regulatory modifications such as the EUAs and concurrent process validation accelerated the approvals of vaccines. To achieve the effective knowledge transfer for collaboration like COVAX, the fair distribution of vaccinations for every country in the world was ensured. The fact is that all these concerns will be crucial for maintaining the preparedness for other future health threats in case the pandemic turns into the endemic phase. If the pharmaceutical sector is to make greater investments in scalable production technology, regional manufacturing events and unified regulations they will be in a position to respond to new public health threats in a more efficient manner. In this abstract, the author discusses the lessons learned and their relevance in future global threats and emphasizes the transformative nature of COVID-19 in the generation of pharmacy manufacture.
Implementation of artificial intelligence in biotechnology for rapid drug discovery and enabling personalized treatment through vaccines and therapeutic products Anirudh Mehta
BULLET : Jurnal Multidisiplin Ilmu Vol. 1 No. 01 (2022): BULLET : Jurnal Multidisiplin Ilmu
Publisher : CV. Multi Kreasi Media

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

A new era of healthcare and biomedical research has been brought about by the merging of biotechnology with artificial intelligence (AI). This integration presents previously unheard-of prospects to expand scientific understanding, expedite medication discovery, and tailor therapies. In this study, we examine the ways in which biotechnology and artificial intelligence might work together to improve healthcare in a number of areas, such as individualized treatment plans, quick drug discovery, and the creation of therapeutic items. We go over how artificial intelligence (AI) algorithms use massive amounts of biological and chemical data to forecast medication success, optimize treatment plans, and speed up the search for new treatments. We also look at how biotechnology can be used to translate AI-driven predictions into interventions that are applicable to clinical settings, such as the creation of customized vaccinations, gene therapies, and products for regenerative medicine. We draw attention to the difficulties and constraints that come with integrating biotechnology and AI in healthcare, such as the complexity and interpretability of the data, ethical issues, legal barriers, and societal ramifications. Lastly, we talk about the potential applications of biotechnology and AI in healthcare going forward, such as the creation of more understandable AI algorithms, the fusion of systems biology and multi-omics data, and the development of customized medical devices and regenerative medicine treatments. We can fully utilize biotechnology and AI to change healthcare delivery, enhance patient outcomes, and influence the course of medicine by tackling these issues and embracing these new approaches.
Co-Authors Varun Choudhary